Trivascular Technologies (TRIV) & Its Peers Head to Head Survey

Trivascular Technologies (NASDAQ: TRIV) is one of 19 public companies in the “Medical Devices & Implants” industry, but how does it weigh in compared to its peers? We will compare Trivascular Technologies to similar businesses based on the strength of its profitability, analyst recommendations, institutional ownership, earnings, dividends, valuation and risk.

Analyst Ratings

Get Trivascular Technologies alerts:

This is a summary of current ratings and target prices for Trivascular Technologies and its peers, as provided by MarketBeat.com.

54.4% of shares of all “Medical Devices & Implants” companies are held by institutional investors. 11.9% of shares of all “Medical Devices & Implants” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Trivascular Technologies and its peers’ net margins, return on equity and return on assets.

Net Margins

Return on Equity

Return on Assets

Trivascular Technologies

-143.61%

-766.90%

-66.97%

Trivascular Technologies Competitors

-99.87%

-92.40%

-29.72%

Earnings and Valuation

This table compares Trivascular Technologies and its peers top-line revenue, earnings per share and valuation.

Gross Revenue

Net Income

Price/Earnings Ratio

Trivascular Technologies

N/A

N/A

-2.04

Trivascular Technologies Competitors

$1.67 billion

$207.76 million

58.15

Trivascular Technologies’ peers have higher revenue and earnings than Trivascular Technologies. Trivascular Technologies is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Trivascular Technologies, Inc. is a medical device company developing and commercializing technologies to advance minimally invasive treatment of abdominal aortic aneurysms (AAA). The Ovation System, the Company’s solution for the treatment of AAA through minimally invasive endovascular aortic repair, or EVAR, is a stent graft platform, providing an alternative to conventional devices. It is designed to specifically address many of the limitations associated with conventional EVAR devices and expand the pool of patients eligible for EVAR. The Company is developing Ovation iX iliac limbs for use with both its Ovation Prime and its Ovation iX and Alto aortic bodies, which are in development. Trivascular is developing Ovation iX aortic bodies for use with both its Ovation Prime and its Ovation iX iliac limbs. The Company is developing an aortic body that together with the iliac limbs makes up the Ovation Alto stent graft.